Nasdaq Biotechnology Ishares ETF (IBB)
$136.69
0.60 (0.44%)
IBB Stock Quote Delayed 30 Minutes
Make Valeant Pharmaceuticals Intl Inc (VRX) Stock Pay YOU
Valeant Pharmaceuticals (VRX) is plunging today. That'd bad news for bulls, but a good chance for you to score income off VRX stock.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
906,470
Day's Range
$136.09 - $137.44
52-Week Range
$111.83 - $141.16
Dividend & Yield
$0.61 (0.45%)
IBB Stock Predictions, Articles, and Nasdaq Biotechnology Ishares ETF News
Wednesday’s Vital Data: Alcoa Inc (AA), Illumina, Inc. (ILMN) and The Coca-Cola Co (KO)
Coca-Cola hasn’t been “it” with investors for much of 2016 and some options traders are betting that’s not about to change anytime soon
Dump Horizon Pharma PLC (HZNP) Stock Now! Don’t Wait!
Horizon Pharma is fading after ugly guidance, and the HZNP stock chart is terrible. Sell this biotech stock before its November report.
2 Ways to Make Bank on Valeant Pharmaceuticals Intl Inc (VRX)
Valeant Pharmaceuticals doesn't know how to settle down, but we can still profit off VRX stock in a somewhat safer manner. Here's how.
Trade of the Day: iShares Nasdaq Biotechnology Index (ETF) (IBB) Is Turning Things Around
It has been a rough year for this biotechnology ETF, but several indicators suggest IBB is a good buy.
Go Long Biotech Stocks for a Donald Trump Win (LABU)
Recently Trump has been gaining in the polls. A Trump win could cause a rally in the biotech sector. Buy calls into the elections.
Celgene Corporation (CELG) – Two Ways to Trade CELG Stock
CELG stock now sits at a critical technical juncture with two paths to take after Celgene experienced a wild ride in late July and August.
Dynavax Technologies Corporation (DVAX) Injected With 20%-Plus Gains
Dynavax Technologies Corporation (DVAX) stock is gaining back what it lost and then some after the pre-holiday-weekend rout. Is this a good time to buy?
The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is on Breakout Watch!
The iShares Nasdaq Biotechnology ETF (IBB) has settled into a constructive-looking phase. The path of least resistance? North!
Amgen, Inc (AMGN) – Amgen Stock Is a Powerhouse
Biotechs such as Amgen stock have been riding high for more than a month. AMGN in particular looks promising for new money.
The iShares Nasdaq Biotechnology Index (ETF) (IBB) — It’s Make-or-Break Time
While the intermediate-term trend remains intact for the IBB etf, earnings season for large biotech companies could be make-or-break.
The iShares Nasdaq Biotechnology Index (ETF) (IBB): Gravity Calls!
Active investors and traders should look to play the iShares Nasdaq Biotechnology Index (ETF) (IBB) to the short side until the picture changes.
Biotech Bloodbath: Ditch XBI, IBB for Now
Biotech ETFs IBB and XBI are in a hurt locker right now. Even if you're bullish on biotechs for the long-term, consider a hedge play or two for now.
IBB: The iShares NASDAQ Biotechnology Index (ETF) Is Still a Buy
Even if Hillary Clinton becomes the next POTUS, biotech stocks won't sink into oblivion -- that's enough reason to buy the IBB ETF.
iShares Nasdaq Biotechnology Index (ETF) (IBB): Just Short It!
The biotech sector has had its ups and downs, but I think there are more downs to come. Short IBB for free.
Trade of the Day: IBB Breaking Down
Some notable technical damage favors more downside in iShares NASDAQ Biotechnology Index (ETF).
Weight of Evidence Points to Stocks Heading Lower
At the very least, the market has limited upside from here.
This Could be a Make-or-Break Week for Stocks
A number of important earnings reports will be key to whether the recent rally can continue.
Biotech May be Bargain Hunters’ Next Target
Buyers seem to be focused on only the most beaten-down sectors.
iShares Nasdaq Biotechnology Index (ETF) (IBB): Nibble on the Long Side
Biotech stocks, after some prolonged weakness, are starting to show promising relative and absolute strength. That means opportunity in the IBB.
